The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006288
Abstract: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in… read more here.
Keywords: ibrutinib; median time; covid; inhibitor ibrutinib ... See more keywords